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eral blood stem cell product collected before treatment on this
study. Two patients achieved complete remission and remain pro-
gression-free more than 5 years after study entry. Four relapsed
and died of progressive disease; all recurred in extraosseous sites
with 2 also having disease in the bone marrow. Median time to
progression was 10 months.
We conclude that treatment with 166Ho DOTMP delivers tar-
geted radiotherapy to the skeleton with an acceptable toxicity
proﬁle. Two patients with bone-only metastases achieved sustained
complete responses. Further studies are warranted to evaluate this
strategy for treatment of bone metastases.
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TANDEM HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL
BLOOD STEM CELL RESCUE (PBSCR) AS CONSOLIDATION THERAPY
FOR HIGH-RISK (PRIMARY UNRESECTABLE PELVIC TUMORS OR MET-
ASTATIC DISEASE) EWING’S SARCOMA PATIENTS
Burke, M.J., Kletzel, M., Jacobsohn, D.A., Duerst, R.E. Children’s
Memorial Hospital, Feinberg School of Medicine, Northwestern Univer-
sity, Chicago, IL.
Methods: Between 1985 and 2004, 14 patients with high-risk
Ewing’s sarcoma received induction chemotherapy, surgery, and
radiation therapy, with 8 of the 14 patients receiving tandem
transplantations. The median age at diagnosis was 14 years (range,
1–17 years) for the 8 patients receiving PBSCR and 9 years (range,
4–14 years) for the 6 patients who did not receive PBSCR. Of the
6 patients who did not receive a stem cell rescue, 5 had primary
pelvic tumors without metastatic disease, and 1 had a nonpelvic
primary tumor with bone metastases. Of the 8 patients who re-
ceived HDC and PBSCR, 6 patients had primary pelvic tumors (3
of them with pulmonary metastases), and the remaining 2 had
primary bone disease outside of the pelvis with bone metastases. Of
the 8 patients who received a transplant, 2 received chemotherapy
only before PBSCR, and 6 received chemotherapy and surgery
before transplantation. Three ablative regimens were used for the
8 patients. Six patients received tandem rescues. Rescue 1 included
etoposide (VP-16), 800 mg/m2/day for 3 days; carboplatin (CP),
667 mg/m2/day for 3 days; and cyclophoshamide (CTX), 1800
mg/m2/day for 2 days. Rescue 2 involved thiotepa (TT), 300
mg/m2/day for 3 days; CTX (n  1), melphalan/CTX (n  4), and
melphalan/TBI (n  1); VP-16, 800 mg/m2/day for 4 days; CTX,
1800 mg/m2/day for 3 days; total body irradiation (TBI), 200 cGy
BID for 3 days (n 1); melphalan, 60 mg/m2/day for 3 days; CTX,
500 mg/m2/day for 4 days (n  1). The median stem cell dose was
1.78  108 mnc/kg (range, 1.0  108 to 2.3  108 mnc/kg).
Results: The mean time to achieve ANC  500 was 13 days
(range, 7–17 days), and the mean time to achieve a platelet count
20K for 7 consecutive days unsupported was 23 days (range, 7–57
days). There were no toxic deaths in the 8 patients who received
PBSCR. Five of the 8 patients who received PBSCR are in com-
plete remission, with a median follow-up of 7.8 years (range,
36–118 months). Of the 6 patients who did not receive PBSCR, 3
continue in complete remission with a median follow-up of 10.5
years (range, 120–132 months). Conclusions: Our results suggest
that high-dose therapy with PBSCR is an effective and feasible
treatment for patients with high-risk Ewing’s sarcoma. A larger
longitudinal study would be helpful to further evaluate this treat-
ment option.
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CD133-POSITIVE HEMATOPOIETIC STEM CELLS “STEMNESS” GENES
CONTAIN MANY GENES MUTATED OR ABNORMALLY EXPRESSED IN
LEUKEMIA
Toren, A.1, Bielorai, B.1, Jacob-Hirsh, J.1, Fisher, T.1, Kreiser, D.1,
Zelikovsky, S.1, Givol, D.2, Itskovitz-Eldor, J.3, Rosenthal, E.1,
Amariglio, N.1, Rechavi, G.1 1Sheba Medical Center, Tel-Hashomer,
Israel; 2Weizmann Institute of Science, Rehovot, Israel; 3Rambam Med-
ical Center, Haifa, Israel.
Several groups have recently used microarray technology to
study the common characteristics of stem cells from different
tissues (“stemness”) and the typical features of stem cells from
various sources (“tissue speciﬁcity”). Most groups focused their
study on mice, used relatively small cDNA microarrays, and used
CD34 as the cell surface marker for hematopoietic stem cells
isolation. We studied HSC cells from cord blood (CB) and periph-
eral blood (PB)characterized by expression of the primitive CD133
antigen, and used the Affymetrix Human Hu133A oligonucleotide
arrays to study the gene expression proﬁle of these cells.
An unsupervised hierarchical clustering of 14,025 “valid” probe
sets showed a clear distinction between the CD133 cells repre-
senting the stem cell population and CD133 cells that represent
various stages of cell differentiation. Comparison of CD133 cells
isolated from CB and PB to CD133 cells identiﬁed 304 genes
that were up-regulated by at least 2-fold in CB and 218 genes in
PB. These genes were considered source-speciﬁc and possibly
relevant to the unique properties of CB- and PB-derived HSC. A
total of 244 genes were found to be up-regulated by at least 2-fold
in the CD133 cells of both CB and PB compared with the
CD133 cells. Comparison of these “stemness” genes to the lists
of “stemness” genes that were identiﬁed by 2 recent studies that
analyzed mainly murine HSC identiﬁed totals of 33 and 65 com-
mon genes. Twenty-four genes were common to another study
that analyzed human HSC.
Among these common “stemness” genes, we identiﬁed several
groups of genes that have an important role in hematopoiesis:
growth factor receptors, a group of transcription factors that in-
cludes several homeobox genes and TGF- target genes, genes
that have an important role in development, and genes involved in
cell growth. Among these 4 groups, we identiﬁed 16 “stemness”
genes (MPL, FLT3, HOXA9, MEIS 1, MLLT3, KIT, TIE,
GATA-2, HOXA5, HOXA10, HLF, MYCN, EVI1, MYB, FHL1,
and HMGA2) that are known to be mutated or abnormally regu-
lated in acute leukemias. It can be suggested that key hematopoi-
etic stemness machinery genes may lead to abnormal proliferation
and leukemia on mutation or change of expression.
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PLEIOTROPHIN IS A KEY SWITCH OF HUMAN MONOCYTES AND BONE
MARROW STEM CELLS INTO ENDOTHERLIAL-LIKE CELLS FOR ANGIO-
GENESIS IN TUMOR GROWTH
Chen, H.1, Zhu, D.1, Campbell, R.A.1, Pan-James, C.1, Wang, C.S.1,
Gordon, M.S.1,2, Bonavida, B.2, Berenson, J.R.1 1Institute for Myeloma
and Bone Cancer Research, West Hollywood, CA; 2UCLA School of
Medicine, Los Angeles, CA.
Multiple myeloma (MM) patients express pleiotrophin (PTN), a
secreted protein that binds CD138, and it is found at high levels in
the serum of MM patients. We have discovered a novel mechanism
leading to blood vessel formation by tumor cells. First, we puriﬁed
human monocytes (CD14) and cultured on collagen I, collagen
IV, ﬁbronectin, or laminin-coated dishes. The cells incubated on
collagen I (but not on the other 3 proteins) with mCSF  PTN
formed tube-like structures with positive staining for Flk-1. Com-
plex lines consisting of multiple rows of elongated Flk-1 cells in
contact with each other were found. In contrast, monocytes incu-
bated with only mCSF or on other substrates remained in sepa-
rated positions. We also cloned human monocytic THP-1 cells
with PTN sense or antisense whole sequencing DNA. We exam-
ined expression by RT-PCR of endothelial cell markers Flk-1,
Tie-2, and vWf and monocyte markers c-fms and CD68. THP-1
cells infected with PTN sense strand expressed high amounts of
Flk-1, Tie-2, and vWf similar to that found in human coronary
artery endothelial cells and lost expression of c-fms and CD68.
Next, we cultured THP1 monocytes with human myeloma
RPMI8226 cells in transwell cultures, serum derived from MM
patients with high serum levels of PTN, cell lines lacking PTN
expression, or normal controls lacking serum PTN. The THP-1
cells exposed to the MM cell line or MM serum showed expression
of endothelial markers. The expression of endothelial markers was
blocked by adding anti-PTN antibody. We also determined
whether PTN could also stimulate differentiation of bone marrow
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stem cells into endothelial cells. The stem cells were derived from
bone marrow by CD34 selection, and were stimulated with either
m-CSF or PTN alone or a combination of m-CSF and PTN or no
treatment for 7 days. Real-time PCR analysis showed that the
m-CSF and PTN combination markedly increased endothelial cell
marker expression and decreased monocyte marker (CD68 and
c-fms) expression in this stem cell population. When induced with
PTN alone, the stem cells exhibited slightly increasing expression
of endothelial markers. These experiments deﬁne a previously
unrecognized novel mechanism leading to angiogenesis in cancer
patients: the transdifferentiation of monocytes into endothelial
cells by a factor highly produced by tumor cells. They also suggest
a potential new speciﬁc target to inhibit angiogenesis—pleiotro-
phin—which may have profound clinical implications.
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BONE MARROW STEM CELL TRANSPLANTATION IN NEURODEGENERA-
TIVE AND CEREBROVASCULAR DISEASE: PRELIMINARY REPORT
Ozbabalik, D.B., Gulbas, Z., Adapinar, B., Ak, I., Gulel, B. Osmangazi
University Medical Faculty, Eskisehir, Turkey.
Stem cells with self-renewal and multilineage potential are con-
sidered good candidates for cell replacement of damaged nervous
tissue in cerebrovascular and neurodegenerative disease. Most of
the knowledge about the role of stem cells in the progression of
these diseases have been based on experimental evidence. Until
now, there has been no human study showing the effectiveness of
stem cell transplantation in neurologic disease. In this study we
attempted to test whether bone marrow stem cells can improve the
functional, radiologic, and metabolic outcomes in patients with
vascular dementia and ischemic stroke with intra-arterial injection.
Seven patients, (3 female and 4 male; mean age  SD, 68.23 
11.2 years) were included in the study. Patients were selected from
among chronic poststroke and/or vascular dementia patients who
did not respond to classical therapy. Barthel, NIH, and MMSE
scales were used to record mental and motor status, and MR and
SPECT were used to record radiologic and metabolic status before
and 30, 60 and 120 days after the procedure. After the patients were
given neurologic examinations, their bone marrow was aspirated,
cultured in Teﬂon bags, and proliferated during 24 hours. Cul-
tured bone marrow was given to patients intra-arterially and an-
giographically under sterile conditions.
Functionally and mentally, all patients showed improvement in
Barthel, NIH, and MMSE scales 60 days after the procedure, but
the differences were not statistically signiﬁcant (ﬁrst Barthel,
9.85 2.67, last Barthel, 11.28 2.69, [P .32]; ﬁrst NIH, 9.00
2.63, last NIH, 7.42  2.19 [P  .16]; ﬁrst MMSE, 10.71  3.73,
last MMSE, 17.00 4.69 [P  .63]).
In terms of radiology, volumetric improvement on MR was seen
after the procedure (Cavalier volumetric method; P  .047). On
SPECT, cerebral metabolism was observed to increase in 3 patients
quantatively. Finally, we observed a trend of clinical improvement in
our patients. But our study has some limitations, such as a small
number of patients. Nonetheless, in light of our ﬁrst results, we can
say that otology bone marrow stem cell transplantation may provide
new hope in the treatment of neurodegenerative disease.
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BIOLUMINESCENT TRACKING OF CANDIDATE LEUKEMIC STEM CELL
ENGRAFTMENT IN IMMUNOCOMPROMISED MICE
Jamieson, C.H.M., Karimi, M., Creusot, R., Fathman, C.G.,
Negrin, R., Weissman, I.L. Stanford University School of Medicine,
Stanford, CA.
Background: We investigated whether leukemic stem cells
(LSCs) involved in CML progression use the beta-catenin pathway
for self-renewal and also whether inhibition of beta-catenin with
axin prevents engraftment of leukemic stem cells in an immuno-
compromised mouse model using bioluminescent tracking. Meth-
ods: We used ﬂuorescence-activated cell sorting (FACS) to isolate
hematopoietic stem cells (HSCs), common myeloid progenitors
(CMPs), granulocyte/macrophage progenitors (GMPs), and
megakaryocyte/erythroid progenitors (MEPs) from normal mar-
row, cord blood, or advanced-phase CML. In vitro replating assays
were used to identify self-renewing cells as candidate leukemic
stem cells, and the dependence of self-renewal on beta-catenin
activation was tested by lentiviral transduction of hematopoietic
progenitors with axin, an inhibitor of the beta-catenin pathway.
CML HSCs, CMPs, GMPs, or CD3438 cells were transduced
with a lentiviral luciferase GFP vector with or without axin, trans-
planted intrahepatically into newborn T-, B-, and NK-deﬁcient
mice and monitored for engraftment via weekly bioluminescent
imaging as well as tail bleeding to detect GFP-positive cells. Re-
sults: When compared with normal marrow, the GMP pool from
patients in blast crisis and imatinib-resistant CML was expanded
and had elevated levels of nuclear beta-catenin. Unlike normal
GMPs, CML GMPs formed self-renewing replatable myeloid col-
onies, and in vitro self-renewal capacity was reduced by enforced
expression of axin. Although CML HSC showed evidence of early
engraftment, committed progenitors, such as GMP, expanded
more readily in vivo. and their growth was inhibited by pretreat-
ment with axin. Conclusions: Activation of beta-catenin in CML
granulocyte/macrophage progenitors likely enhances their self-
renewal and leukemic activity. Speciﬁc beta-catenin inhibitors such
as axin block this aberrant self-renewal activity in vitro and in vivo.
Finally, the use of bioluminescent imaging of leukemic/cancer
stem cell engraftment in vivo using a newborn immunocompro-
mised mouse model provides a robust tool for assessing response of
cancer stem cells to molecularly targeted therapy.
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EFFECTS AND KINETICS OF ANTI–C-KIT MONOCONAL ANTIBODY
ACK-2 ON HEMATOPOIESIS AND HEMATOPOIETIC PROGENITORS AND
ITS ABILITY TO CONDITION FOR BONE MARROW TRANSPLANTATION
Kraft, D.L., Weissman, I.L. Stanford University School of Medicine,
Stanford University, CA.
Background: The stem cell receptor factor receptor c-Kit is ex-
pressed on hematopoeitic stem cell (HSC) and progenitor cell popu-
lations. ACK-2 is an anti-mouse c-kit mAb that has been shown to
antagonize the function of c-kit and deplete the bone marrow of
treated mice. We wished to characterize the effect and kinetics of
ACK-2 on the peripheral blood cell counts and marrow HSC and
progenitor populations. We also tested the hypothesis that treatment
with ACK-2 may serve as a novel means of nonmyeloablative condi-
tioning for HSC transplantation.Methods: Adult C57/BLmice were
injected either intravenously or intraperitonealy (IP) with 1 mg of
ACK2 mAb on days 0, 2, and 4. Peripheral blood cell counts, includ-
ing WBC differentials, were followed over time in recipient mice.
Peripheral blood and bonemarrow was analyzed at day 7, andmarrow
was analyzed for fraction and proportions of HSC, common myeloid
progenitors (CMPs), granulocyte macrophage progenitors (GMPs),
and macrophage erythrocyte progenitors (MEPs). A subset of Ly5.1
mice that had received ACK2mAb on days 0, 2, and 4 received a bone
marrow transplantation on day 7 with 1106 bone marrow cells from
a congenic Ly5.2 donor. Results: Both IV and IP administration of
ACK-2 resulted in rapid development of anemia, neutropenia, and
thrombocytopenia (see the table for results). Analysis of peripheral
blood revealed a decrease in Mac-1 cells from 12.2% of circulating
WBCs in untreated controls to 3.1% at day 7, whereas the proportion
of B220 B cells increased frommean of 49.7% in controls to 72.7%.
The fraction of circulating T cells decreased from 24.5% to 11.1% at
day 7. The bone marrow fraction of KTLS HSC decreased from
0.07% of total marrow cells in controls to 0.003% in ACK-2–treated
mice. The marrow fractions of CMP and GMP all decreased in
treatedmice, with a proportional drop in CMP progenitors from 12%
in untreated mice to 4.7% in treated mice. ACK-2–treated mice
transplanted with Ly5.2 congenic marrow and analyzed at D21
showed no evidence of donor-derived cells in the peripheral blood,
compared with 83% Ly5.2 donor-derived cells in control mice re-
ceiving 9 Gy of radiation. Coclusions: The anti–c-kit mAb ACK-2
rapidly induces anemia, neutropenia, and thrombocytopenia with cor-
relating decreases in the numbers of marrow HSC and other progen-
itor populations. Despite the ablative action of the ACK-2 on marrow
populations, it does not appear to enable engraftment of syngeneic
bone marrow.
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